Acquisition and $200M financing drive VT-7208 phase II trials
Processa Pharmaceuticals says a major acquisition plus $200 million financing will support parallel phase II trials of VT-7208, a BTK inhibitor for food allergy, CSU, and relapsing MS, with key readouts expected in 2027–2028.